eTable 1. Overview of new and identified systematic reviews and GRADE tables.
| Review on | Firstround? | Second round? | GRADE table? | No. of GRADE tables | Place of entry in expert material |
| From: PIM Austria—project report | |||||
| PPI | No | Yes | Second round | 1 | A02BC PPI |
| Benzodiazepines | No | No | No | ||
| ● Comment: Irrelevant in second round due to lack of discrepancy between review and expert assessment | |||||
| Alpha blockers | No | Yes | Second round | 1 | G04CA alpha-adrenoceptor antagonists |
| ● Comment: Not entered for individual substances | |||||
| Ginkgo biloba | No | No | No | ||
| ● Comment: Irrelevant in second round due to lack of discrepancy between review and expert assessment | |||||
| Anticholinergic urologics and beta-3-adrenoceptor agonists | No | No | No | ||
| ● Comment: Irrelevant in second round due to lack of discrepancy between review and expert assessment | |||||
| Imidazoline receptor agonists | No | No | No | ||
| ● Comment: Irrelevant in second round due to lack of discrepancy between review and expert assessment | |||||
| Tramadol | No | Yes | Second round | 1 | N02AX02 Tramadol |
| Sulfonylureas | No | No | No | ||
| ● Comment: Irrelevant in second round due to lack of discrepancy between review and expert assessment | |||||
| Z substances | No | No | No | ||
| ● Comment: Irrelevant in second round due to lack of discrepancy between review and expert assessment | |||||
| Pregabalin | No | Yes | Second round | 1 | N03AX16 pregabalin |
| Aldosterone antagonists | No | Yes | Second round | 1 | C03DA aldosterone antagonists |
| ● Comment: Not entered for individual substances being evaluated | |||||
| From: generic review on aging | |||||
| Anabolic steroids after hip fracture | Yes | No | First round | 1 | G03BA03 testosterone |
| Second-generation antipsychotics: severe side effects | Yes | Yes | First round Second round |
1 | N05A antipsychotics |
| Second-generation antipsychotics: mortality | |||||
| ● Comment: Not entered for individual substances being evaluated | |||||
| Antibiotics in urinary tract infections | Yes | Yes | First round Second round |
1 | J01 antibiotics for systemic use |
| ● Comment: Not entered for individual substances being evaluated | |||||
| Laxatives and iatrogenic falls | Yes | Yes | First round Second round |
1 | A06A medications to treat constipation |
| ● Comment: Not entered for individual substances being evaluated | |||||
| Antihistamines and falls/fractures | Yes | Yes | First round Second round |
1 | R06A antihistamines for systemic use |
| ● Comment: Not entered for individual substances being evaluated | |||||
| Atypical antipsychotics BPSD | Yes (risperidone) |
Yes (risperidone) |
First round Second round |
1 | N05AX08 risperidone |
| Antidepressants in patients aged ≥ 65 years | Yes (duloxetine) |
Yes (duloxetine) |
First round Second round |
1 | N06AX21 duloxetine |
| From: PRIMA-eDS and update/new research | |||||
| DOAC | Yes (text form) |
No | No | B01AA vitamin-K antagonists | |
| ● Comment: Not entered for individual substances being evaluated | |||||
| DPP-4 | Yes (text form) |
Yes | Second round | 2 | A10BH DPP-4 inhibitors |
| ● Comment: Two GRADE PDFs, one for each control | |||||
| From: PRIMA-eDS | |||||
| Beta-blockers | Yes | Yes | First round Second round |
2 | C07A beta-blockers |
| ● Comment: Not entered for individual substances being evaluated Two GRADE PDFs, one for each control | |||||
| Metformin | Yes | No | First round | 5 | A10BA02 metformin |
| ● Comment: Five GRADE PDFs, one for each control | |||||
| Total | 21 | ||||
BPSD, Behavioral and psychological symptoms of dementia; DOAC, direct oral anticoagulants; DPP-4, dipeptidylpeptidase-4; PPI, proton pump inhibitors